eFFECTOR Therapeutics Future Growth
Future criteria checks 0/6
eFFECTOR Therapeutics is forecast to grow earnings at 3.9% per annum. EPS is expected to grow by 98.5% per annum.
Key information
3.9%
Earnings growth rate
98.5%
EPS growth rate
| Biotechs earnings growth | 21.1% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 19 Apr 2024 |
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | N/A | -34 | -36 | -19 | 1 |
| 12/31/2024 | N/A | -32 | -31 | -25 | 2 |
| 12/31/2023 | N/A | -36 | -30 | -30 | N/A |
| 9/30/2023 | 1 | -36 | -31 | -31 | N/A |
| 6/30/2023 | 2 | -37 | -31 | -31 | N/A |
| 3/31/2023 | 4 | -36 | -27 | -27 | N/A |
| 12/31/2022 | 4 | -23 | -26 | -26 | N/A |
| 9/30/2022 | 3 | 6 | -24 | -24 | N/A |
| 6/30/2022 | 3 | 24 | -25 | -25 | N/A |
| 3/31/2022 | 1 | 25 | -26 | -26 | N/A |
| 12/31/2021 | 1 | 16 | -25 | -25 | N/A |
| 9/30/2021 | 1 | -4 | -28 | -27 | N/A |
| 6/30/2021 | 1 | -20 | -26 | -26 | N/A |
| 3/31/2021 | 16 | -7 | -8 | -8 | N/A |
| 12/31/2020 | 42 | 0 | 14 | 14 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: EFTR is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: EFTR is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: EFTR is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if EFTR's revenue is forecast to grow faster than the US market.
High Growth Revenue: EFTR is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if EFTR's Return on Equity is forecast to be high in 3 years time